Issue 11, 2024

Bispecific FpFs: a versatile tool for preclinical antibody development

Abstract

We previously described FpFs [1 with combining low line] (Fab–PEG–Fab) as binding mimetics of IgGs. FpFs are prepared with di(bis-sulfone) conjugation reagents [3 with combining low line] that undergo disulfide rebridging conjugation with the accessible disulfide of each Fab (Scheme 1). We have now prepared bispecific FpFs [2 with combining low line] (bsFpF and Fab1–PEG–Fab2) as potential bispecific antibody mimetics with the intent that bsFpFs could be used in preclinical antibody development since sourcing bispecific antibodies may be challenging during preclinical research. The di(bis-sulfone) reagent [3 with combining low line] was first used to prepare a bsFpF [2 with combining low line] by the sequential conjugation of a first Fab and then a second Fab to another target (Scheme 2). Seeking to improve bsFpF synthesis, the asymmetric conjugation reagent, bis-sulfone bis-sulfide [1 with combining low line][6 with combining low line], with different thiol conjugation reactivities at each terminus (Scheme 4) was examined and the bsFpFs appeared to be formed at similar conversion to the di(bis-sulfone) reagent [3 with combining low line]. To explore the advantages of using common intermediates in the preparation of bsFpF families, we investigated bsFpF synthesis with a protein conjugation–ligation approach (Scheme 5). Reagents with a bis-sulfone moiety for conjugation on one PEG terminus and a ligation moiety on the other terminus were examined. Bis-sulfone PEG trans-cyclooctene (TCO) [2 with combining low line][8 with combining low line] and bis-sulfone PEG tetrazine (Tz) [3 with combining low line][0 with combining low line] were used to prepare several bsFpFs targeting various therapeutic targets (TNF-α, IL6R, IL17, and VEGF) and tissue affinity targets (hyaluronic acid and collagen II). Surface plasmon resonance (SPR) binding studies indicated that there was little difference between the dissociation rate constant (kd) for the unmodified Fab, mono-conjugated PEG–Fab and the corresponding Fab in a bsFpF. The Fab association rate (ka) in the bsFpF was slower than for PEG–Fab, which may be because of mass differences that influence SPR results. These observations suggest that each Fab will bind to its target independently of the other Fab and that bsFpF binding profiles can be estimated using the corresponding PEG–Fab conjugates.

Graphical abstract: Bispecific FpFs: a versatile tool for preclinical antibody development

Supplementary files

Article information

Article type
Paper
Submitted
18 Jun 2024
Accepted
08 Sep 2024
First published
27 Sep 2024
This article is Open Access
Creative Commons BY-NC license

RSC Chem. Biol., 2024,5, 1147-1164

Bispecific FpFs: a versatile tool for preclinical antibody development

M. Collins, N. Ibeanu, W. R. Grabowska, S. Awwad, P. T. Khaw, S. Brocchini and H. Khalili, RSC Chem. Biol., 2024, 5, 1147 DOI: 10.1039/D4CB00130C

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements